Dosage protocol · Immune & Inflammation
KPV 10 mg
Typical daily range: 200–500 mcg once daily (gradual titration recommended).
- Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration.
- Typical daily range: 200–500 mcg once daily (gradual titration recommended).
- Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.33 mcg on a U‑100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F) or below; after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 30 days; avoid freeze–thaw cycles.
Reconstitution
KPV dosage chart
| Week | Dose | Draw |
|---|---|---|
| Week 1 | 200 mcg | 6 units0.06 mL |
| Week 2 | 300 mcg | 9 units0.09 mL |
| Week 3 | 400 mcg | 12 units0.12 mL |
| Weeks 4–8 | 500 mcg | 15 units0.15 mL |
How much to draw
The Draw column shows exactly where to stop on a U-100 insulin syringe. Different vial size or dose? The calculator below recomputes it live.
Supplies needed
Supplies needed
Peptide vial
The lyophilized compound
Bacteriostatic water
For reconstitution
U-100 insulin syringes
One per injection
Alcohol swabs
Stopper + site each time
How it works
KPV is one of the shortest peptides studied for potential therapeutic relevance: a tripeptide made of lysine, proline, and valine. It corresponds to the C-terminal sequence of alpha-melanocyte-stimulating hormone (alpha-MSH), a hormone peptide long studied for its role in immune and inflammatory signaling.[2]
Because it shares this fragment with alpha-MSH, KPV is discussed almost entirely within anti-inflammatory peptide research rather than as a growth-hormone-related or metabolic compound. It is not a therapeutic protein or an approved drug; it is a small research molecule whose biological interest comes from a mechanistic link to melanocortin biology rather than from any clinical track record of its own.
Benefits & side effects
The most cited KPV research is a 2008 study reporting that PEPT1-mediated uptake of the tripeptide reduced intestinal inflammation in experimental colitis models.[3] Related work has examined KPV and alpha-MSH-derived fragments in cell and animal systems relevant to skin inflammation and cytokine signaling.[2] This body of work is genuinely useful for generating hypotheses about gut and skin inflammation.
What is missing is human clinical evidence. Searches of ClinicalTrials.gov and FDA drug databases do not show KPV positioned as an established therapy for inflammatory bowel disease, psoriasis, dermatitis, or any other condition, and it is not listed in clinical guidelines alongside approved treatments for Crohn's disease or ulcerative colitis.[9] Animal colitis models, in particular, do not fully reproduce the genetics, chronic relapsing course, and microbiome complexity of human inflammatory bowel disease.
Calculator
Plan your own dose
Reconstituting a different vial size or targeting a different dose? Run the numbers.